Boston Scientific to acquire Penumbra for ~$14.5B enterprise value ($374/share)

BOSTON SCIENTIFIC CORP

Deal consideration: ~73% cash, ~27% stock; $374 per Penumbra share; enterprise value ~$14.5B.
Penumbra Q4 2025 revenue growth 21.4-22.0%; FY2025 revenue ~$1.4B (+17.3-17.5% YoY).
Transaction expected to close in 2026; subject to Penumbra stockholder approval and customary conditions.
First full year adj. EPS dilutive $0.06-0.08; neutral to slightly accretive in year two.
Expands Boston Scientific into mechanical thrombectomy and neurovascular adjacencies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.